
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co is well-positioned for growth, benefiting from the projected expansion of the ophthalmic surgical and diagnostic devices market, which is expected to reach $20.1 billion by 2025 at a compound annual growth rate of 2.9%. The company's implantable Collamer lenses (ICLs) are experiencing significant growth in market share, increasing from 14.3% in 2019 to a projected 26.5% in 2025, driven by their advantages over traditional corneal laser procedures. Additionally, the recent amended merger agreement with Alcon, raising the acquisition price to $30.75, reflects confidence in Staar's recovery and growth trajectory, enhancing its competitive positioning within the industry.
Bears say
Staar Surgical Co. is facing significant challenges characterized by declining revenue, notably an unprecedented 99% year-over-year drop in Chinese sales during the first quarter of 2025, which has severely impacted the company's overall financial performance. Despite some recovery in subsequent quarters, the company continues to exhibit EBITDA losses and cash consumption, coupled with strategic uncertainty, stalling any prospects for the sustained growth necessary for a premium valuation. Furthermore, the combination of market skepticism regarding the turnaround narrative and increasing competition in China poses substantial risk, suggesting that Staar Surgical's stock may remain under pressure as investors reassess the company's growth potential and execution capabilities.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares